MX9801189A - Uso de inhibidores oxido-ciclasa de escualeno para disminuir el colesterol en la sangre. - Google Patents
Uso de inhibidores oxido-ciclasa de escualeno para disminuir el colesterol en la sangre.Info
- Publication number
- MX9801189A MX9801189A MX9801189A MX9801189A MX9801189A MX 9801189 A MX9801189 A MX 9801189A MX 9801189 A MX9801189 A MX 9801189A MX 9801189 A MX9801189 A MX 9801189A MX 9801189 A MX9801189 A MX 9801189A
- Authority
- MX
- Mexico
- Prior art keywords
- oxido
- phenyl
- squalene cyclase
- blood cholesterol
- lower blood
- Prior art date
Links
- 108010059597 Lanosterol synthase Proteins 0.000 title abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title 2
- 239000008280 blood Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- -1 oxy, thio, sulphinyl Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000005864 Sulphur Chemical group 0.000 abstract 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 abstract 1
- 239000001301 oxygen Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Silver Salt Photography Or Processing Solution Therefor (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Un compuesto de formula I, o una sal farmacéuticamente aceptable del mismo, en donde G, T1, T2 y T3 se seleccionan de CH y N; siempre que T2 y T3 no sean ambos CH; A se selecciona de un enlace directo y de alquileno de (1-4C); X se selecciona de oxi, tio, sulfinilo, sulfonilo, carbonilo, carbonilamino, N-di-alquilcarbonilamino de (1-6C), sulfonamido, alquilmetileno, alquilmetileno de (1-4C) y di-alquilmetileno de (1-6C), y cuando T2 es CH, X también puede seleccionarse de aminosulfonilo y oxicarbonilo; Q se selecciona de cicloalquilo de (5-7C), una porcion heterocíclica que contiene hasta 4 heteroátomos seleccionados de nitrogeno, oxígeno y azufre; fenilo, naftilo, fenilalquilo de (1-4C) y fenilalquileno de (2-6C); para la fabricacion de un medicamento para el tratamiento de enfermedades o condiciones médicas, en las cuales se desea la inhibicion de oxido-ciclasa de escualeno.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9516709.4A GB9516709D0 (en) | 1995-08-15 | 1995-08-15 | Medicament |
| PCT/GB1996/001985 WO1997006802A1 (en) | 1995-08-15 | 1996-08-14 | Use of oxido-squalene cyclase inhibitors to lower blood cholesterol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9801189A true MX9801189A (es) | 1998-04-30 |
Family
ID=10779268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9801189A MX9801189A (es) | 1995-08-15 | 1996-08-14 | Uso de inhibidores oxido-ciclasa de escualeno para disminuir el colesterol en la sangre. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6090813A (es) |
| EP (1) | EP0844877B1 (es) |
| JP (1) | JPH11511161A (es) |
| CN (1) | CN1193276A (es) |
| AT (1) | ATE287715T1 (es) |
| AU (1) | AU6748596A (es) |
| CA (1) | CA2226735A1 (es) |
| DE (1) | DE69634254T2 (es) |
| GB (1) | GB9516709D0 (es) |
| IL (1) | IL123244A0 (es) |
| MX (1) | MX9801189A (es) |
| WO (1) | WO1997006802A1 (es) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL115420A0 (en) | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
| WO1997028128A1 (en) * | 1996-02-02 | 1997-08-07 | Zeneca Limited | Heterocyclic compounds useful as pharmaceutical agents |
| GB9602166D0 (en) * | 1996-02-02 | 1996-04-03 | Zeneca Ltd | Aminoheterocyclic derivatives |
| GB9602294D0 (en) * | 1996-02-05 | 1996-04-03 | Zeneca Ltd | Heterocyclic compounds |
| ATE230399T1 (de) * | 1996-08-14 | 2003-01-15 | Astrazeneca Ab | Substituierte pyrimidinderivate und ihre pharmazeutische anwendung |
| UA56197C2 (uk) | 1996-11-08 | 2003-05-15 | Зенека Лімітед | Гетероциклічні похідні |
| AU5999698A (en) * | 1997-02-13 | 1998-09-08 | Zeneca Limited | Heterocyclic compounds useful as oxido-squalene cyclase inhibitors |
| US6391880B1 (en) | 1997-02-13 | 2002-05-21 | Zeneca Limited | Heterocyclic compounds useful as oxido-squalene cyclase inhibitors |
| GB9715895D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic compounds |
| GB9715892D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic compounds |
| KR20010015639A (ko) | 1997-09-30 | 2001-02-26 | 스즈키 다다시 | 술포닐 유도체 |
| AU745425B2 (en) | 1998-01-27 | 2002-03-21 | Aventis Pharmaceuticals Inc. | Substituted oxoazaheterocyclyl factor Xa inhibitors |
| GB9902989D0 (en) | 1999-02-11 | 1999-03-31 | Zeneca Ltd | Heterocyclic derivatives |
| JP4216502B2 (ja) | 2000-03-24 | 2009-01-28 | ファルマシア コーポレーション | 酸化窒素シンターゼ阻害剤として有用なアミジノ化合物 |
| TWI290136B (en) | 2000-04-05 | 2007-11-21 | Daiichi Seiyaku Co | Ethylenediamine derivatives |
| US6787668B2 (en) | 2000-04-13 | 2004-09-07 | Pharmacia Corporation | 2-amino-4,5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
| US6545170B2 (en) | 2000-04-13 | 2003-04-08 | Pharmacia Corporation | 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
| AR032318A1 (es) | 2000-04-13 | 2003-11-05 | Pharmacia Corp | Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa |
| AR034120A1 (es) | 2000-04-13 | 2004-02-04 | Pharmacia Corp | Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico |
| US6956131B2 (en) | 2000-04-13 | 2005-10-18 | Pharmacia Corporation | 2-amino-3, 4 heptenoic compounds useful as nitric oxide synthase inhibitors |
| AR030416A1 (es) | 2000-04-13 | 2003-08-20 | Pharmacia Corp | COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA |
| US6495544B2 (en) | 2000-08-01 | 2002-12-17 | Pharmacia Corporation | Homoiminopiperidinyl hexanoic acid inhibitors of inducible nitric oxide synthase |
| TWI290130B (en) | 2000-09-15 | 2007-11-21 | Pharmacia Corp | 2-Amino-2alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| AR031129A1 (es) | 2000-09-15 | 2003-09-10 | Pharmacia Corp | Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa |
| DE60144284D1 (de) | 2000-11-01 | 2011-05-05 | Millennium Pharm Inc | Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung |
| WO2003000657A1 (fr) | 2001-06-20 | 2003-01-03 | Daiichi Pharmaceutical Co., Ltd. | Derives de diamine |
| CN1181065C (zh) * | 2002-05-08 | 2004-12-22 | 上海医药工业研究院 | 芳烷甲酰烷基哌嗪衍生物及其作为脑神经保护剂的应用 |
| CA2508840A1 (en) | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
| DK1615909T3 (da) | 2003-04-23 | 2008-11-17 | Glaxo Group Ltd | Piperazin-derivater og deres anvendelse til behandling af neurologiske og psykiatriske sygdomme |
| WO2005113174A1 (ja) * | 2004-05-21 | 2005-12-01 | Kao Corporation | レジンコーテッドサンド |
| US7622579B2 (en) | 2004-06-28 | 2009-11-24 | Janssen Pharmaceutica Nv | Hetero isonipecotic modulators of vanilloid VR1 receptor |
| JP4550522B2 (ja) * | 2004-08-19 | 2010-09-22 | スガイ化学工業株式会社 | ６−クロロ−２−ナフタレンスルホン酸の製造方法 |
| SI1899322T1 (sl) | 2005-06-28 | 2010-01-29 | Sanofi Aventis | Izokinolinski derivati kot inhibitorji Rho-kinaze |
| MX2007016545A (es) * | 2005-06-30 | 2008-02-21 | Prosidion Ltd | Agonistas del receptor acoplado a la proteina g. |
| BRPI0613861B8 (pt) | 2005-07-26 | 2021-05-25 | Sanofi Aventis | derivados de isoquinolona piperidinil-substituídos como inibidores de rho-cinase |
| PL1912949T3 (pl) | 2005-07-26 | 2012-01-31 | Sanofi Sa | Pochodne cykloheksyloaminoizochinolonu jako inhibitory kinazy RHO |
| AU2006275568A1 (en) * | 2005-08-02 | 2007-02-08 | Neurogen Corporation | Dipiperazinyl ketones and related analogues |
| MX2009006517A (es) | 2006-12-27 | 2009-06-26 | Sanofi Aventis | Nuevos derivados de isoquinolina e isoquinolinona sustituidos. |
| CA2673916C (en) | 2006-12-27 | 2015-02-17 | Sanofi-Aventis | Substituted isoquinolone and isoquinolinone derivatives as inhibitors of rho-kinase |
| CN101578266B (zh) | 2006-12-27 | 2013-10-30 | 塞诺菲-安万特股份有限公司 | 环烷基胺取代的异喹啉和异喹啉酮衍生物 |
| MX2009005966A (es) | 2006-12-27 | 2009-06-15 | Sanofi Aventis | Derivados de isoquinolona sustituidos con cicloalquilamina. |
| AU2007338410B2 (en) | 2006-12-27 | 2012-08-16 | Sanofi-Aventis | Cycloalkylamine substituted isoquinoline derivatives |
| RU2009128690A (ru) | 2006-12-27 | 2011-02-10 | Санофи-Авентис (Fr) | Новые замещенные производные изохинолина и изохинолинона |
| JP5208963B2 (ja) | 2007-01-10 | 2013-06-12 | エフ．ホフマン−ラ ロシュ アーゲー | キマーゼ阻害剤としてのスルホンアミド誘導体 |
| CN102131785B (zh) | 2008-06-24 | 2014-10-29 | 赛诺菲-安万特 | 6-取代的异喹啉和异喹啉酮 |
| CA2728137C (en) | 2008-06-24 | 2016-10-18 | Sanofi-Aventis | Substituted isoquinolines and isoquinolinones as rho kinase inhibitors |
| MX2010013867A (es) | 2008-06-24 | 2011-02-24 | Sanofi Aventis | Derivados de isoquinolina e isoquinolinona bi- y policiclicos sustituidos. |
| GB0818241D0 (en) | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use |
| CN103596570B (zh) | 2010-12-27 | 2018-02-16 | 密苏里大学管委会 | 作为抗癌治疗的蛋白质靶的氧化鲨烯环化酶 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT340933B (de) * | 1973-08-20 | 1978-01-10 | Thomae Gmbh Dr K | Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze |
| US4167567A (en) * | 1978-05-05 | 1979-09-11 | The Upjohn Company | Antihypertensive 4-aminoquinolines |
| IT1245712B (it) * | 1991-04-09 | 1994-10-14 | Boehringer Mannheim Italia | Ammine eterocicliche utili terapia dell'asma e dell'infiammazione delle vie aeree |
| FR2676054B1 (fr) * | 1991-05-03 | 1993-09-03 | Sanofi Elf | Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5371091A (en) * | 1992-08-31 | 1994-12-06 | Bristol-Myers Squibb Company | Heteroaromatic amine thrombin inhibitors |
| IL115420A0 (en) * | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
| IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| IL117580A0 (en) * | 1995-03-29 | 1996-07-23 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them |
| US5856326A (en) * | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
-
1995
- 1995-08-15 GB GBGB9516709.4A patent/GB9516709D0/en active Pending
-
1996
- 1996-08-14 JP JP9509050A patent/JPH11511161A/ja not_active Ceased
- 1996-08-14 CA CA002226735A patent/CA2226735A1/en not_active Abandoned
- 1996-08-14 AU AU67485/96A patent/AU6748596A/en not_active Abandoned
- 1996-08-14 DE DE69634254T patent/DE69634254T2/de not_active Expired - Fee Related
- 1996-08-14 US US09/011,718 patent/US6090813A/en not_active Expired - Fee Related
- 1996-08-14 CN CN96196278A patent/CN1193276A/zh active Pending
- 1996-08-14 IL IL12324496A patent/IL123244A0/xx unknown
- 1996-08-14 WO PCT/GB1996/001985 patent/WO1997006802A1/en active IP Right Grant
- 1996-08-14 AT AT96927782T patent/ATE287715T1/de not_active IP Right Cessation
- 1996-08-14 MX MX9801189A patent/MX9801189A/es unknown
- 1996-08-14 EP EP96927782A patent/EP0844877B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69634254T2 (de) | 2006-01-12 |
| IL123244A0 (en) | 1998-09-24 |
| AU6748596A (en) | 1997-03-12 |
| EP0844877B1 (en) | 2005-01-26 |
| EP0844877A1 (en) | 1998-06-03 |
| CA2226735A1 (en) | 1997-02-27 |
| ATE287715T1 (de) | 2005-02-15 |
| JPH11511161A (ja) | 1999-09-28 |
| CN1193276A (zh) | 1998-09-16 |
| US6090813A (en) | 2000-07-18 |
| DE69634254D1 (de) | 2005-03-03 |
| GB9516709D0 (en) | 1995-10-18 |
| WO1997006802A1 (en) | 1997-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9801189A (es) | Uso de inhibidores oxido-ciclasa de escualeno para disminuir el colesterol en la sangre. | |
| CA2107014A1 (en) | Therapeutic Agent for Parkinson's Disease | |
| KR940007270B1 (en) | Quinazoline derivatives | |
| EP0721944A4 (en) | IMIDAZOLIDINE DERIVATIVES AND THEIR USE | |
| MY131696A (en) | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists | |
| IL109615A0 (en) | Polypeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
| MX9701685A (es) | Nuevos derivados de bencimidazol que tienen la actividad de inhibicion de la fosfodiestearasa cgmp. | |
| TW243449B (es) | ||
| ZA86262B (en) | Therapeutic agents | |
| UA32427C2 (uk) | Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань | |
| GB9318935D0 (en) | Heterocyclic derivatives | |
| NZ332136A (en) | Phenylalkylcarboxylic acid derivatives useful for treating hyperglycemia | |
| UA66842C2 (uk) | Похідні піридину як інгібітори pde iv | |
| DE3162053D1 (en) | N-acyl peptide compounds, processes for the preparation thereof and pharmaceutical compositions containing them | |
| KR900006282A (ko) | 피롤리딘 유도체 | |
| EP0525203A4 (en) | Substituted sulfonamide derivative or pharmaceutical composition containing the same | |
| EP0420086A3 (en) | Pyrimidoindole derivatives and processes for preparation thereof | |
| MX9802679A (es) | Derivados de ditiolan, su preparacion y su efecto terapeutico. | |
| CA2198266A1 (en) | Novel benzimidazole derivatives |